What is vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)?

Question

Accepted Answer

Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) Defined

Vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) is a rare condition characterised by a significant reduction in the number of platelets, the blood components responsible for clotting. This depletion impairs the body's ability to form clots, potentially leading to excessive bleeding. In some instances, this thrombocytopenia can result in the formation of blood clots within the vessels that drain blood from the brain.
Mechanism of VIPIT

The development of VIPIT is believed to stem from an overreaction of the immune system. Specifically, the AstraZeneca vaccine is thought to trigger the production of antibodies that mistakenly target and interact with platelets. These antibodies cause platelets to aggregate, forming clots. This process depletes the number of circulating platelets, leading to the characteristic thrombocytopenia. The underlying biological mechanism is considered similar to that observed in heparin-induced thrombocytopenia, where antibodies bind to platelets and can precipitate clot formation.
Presentation and Demographics

VIPIT typically manifests within a timeframe of 4 to 20 days following vaccination. Initial observations suggest a higher association with women under the age of 65. Symptoms can include severe headaches, abdominal pain, seizures, and visual disturbances, which are also symptoms of non-vaccine-related thrombocytopenia.
Incidence and Risk

The incidence of VIPIT is estimated to be exceptionally low, potentially as rare as one in 500,000 individuals, although current data is acknowledged as incomplete. For comparison, naturally occurring thrombocytopenia affects approximately one in 30,000 adults annually in the United States. Some countries, like Norway, have reported higher rates, with one in 25,000 vaccinated adults under 65 experiencing low platelet counts, bleeding, and widespread thromboses. Despite these rare occurrences, regulatory bodies such as the European Medicines Agency and the World Health Organisation maintain that the benefits of the AstraZeneca vaccine outweigh the risks for the general adult population.

Reading history

Hide →

This history is cleared when the page is closed.

What is vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends